Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays.

Abstract excerpt

INTRODUCTION: Detection of epidermal growth factor receptor (EGFR) mutation has become the most critical molecular test in managing patients with advanced lung adenocarcinoma. Whether patients with discrepant EGFR mutation results determined by low- and high-sensitivity methods have different clinical outcomes with EGFR tyrosine kinase inhibitor (TKI) treatment needs to be further evaluated. METHODS: Genomic DNA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma
• Share to Adenocarcinoma of Lung